OCT 24, 2017 09:00 AM PDT

WEBINAR: Genome Editing for Functional Genomics and Drug Discovery

SPONSORED BY: Thermo Fisher Scientific
  • Senior Staff Scientist, Cell Biology R&D, Thermo Fisher Scientific
      Chetana is a Senior Staff Scientist at Thermo Fisher Scientific, with over 15 years of experience in the field of Cell Biology and has been with the company for 10 years. Before joining the Services team, she led the development of several new products ranging from cell based assays for GPCR, BacMam based assays to 3D cellular models. As a technical lead on services team, she supports project design and execution. Her experience covers a broad range of applications from cell engineering to disease modeling.
    • Scientist, Thermo Fisher Scientific
        Previous to his current tenure as a Scientist in the Synthetic Biology business of Thermo Fisher Scientific, Sanjay Kumar accumulated > 10 years of experience studying the cellular response to DNA damage. That work began with Sanjay's pursuit of his doctorate degree, resulting in his PhD from the Cancer Genetics Department of the Roswell Park Cancer Institute in Buffalo NY. At Roswell, Sanjay identified the mechanism of replication fork slowdown upon DNA damage in fission yeast. His work in the DNA damage field continued with postdoctoral research at Caltech in Pasadena CA where he dissected the role of the Rif1 protein in the vertebrate intra-S-phase checkpoint. Additionally, Sanjay holds a business degree in Bioscience Management from the Keck Graduate Institute. As part of the scientific team at Thermo Fisher Scientific, he has contributed to the commercial development of Genome Editing tools such as TALENs and CRISPRs. Most recently he played a key role in the development of the GeneArt® CRISPR Nuclease mRNA and supporting early access to GeneArt Platinum Cas9 as well as TrueCut Cas9 V2. Currently a leader of Cell Line Engineering group within Custom Services Team, his role requires Sanjay to lead several custom cell engineering projects and streamline/adapt these workflows for a variety of applications.


      DATE: October 24, 2017
      TIME: 09:00am PDT, 12:00pm EDT

      Does your work involve disease models? Do you have a need to introduce specific genomic changes in the cells of your choice? Do you want to knock-out or knock-in a gene in your cellular model? If the answer to any of these questions is “yes” or you are just curious to learn about it, then this is a must-watch webinar for you.

      The last few years have seen dramatic technical leaps in the ability to precisely manipulate the mammalian genome. Development of precision genome editing tools like TALENs (Transcription Activator-Like Effector Nuclease) and CRISPRs (Clustered Regularly Interspaced Palindromic Repeats) have enabled the specific introduction of targeted DNA double-strand breaks (DSBs). Cellular machinery primarily repairs these breaks via the non-homologous end joining pathway which can introduce small insertions or deletions at the break site (thereby causing a disruption). In the presence of a suitable donor DNA template, cellular machinery can also perform the break repair through the homology-directed repair pathway and precisely introduce the donor DNA molecule into the break site (knock-in). Various cell engineering strategies can be developed by leveraging the targeted DNA DSBs and DNA repair machinery and both TALENs and CRISPRs have been used to generate gene disruptions, perform SNP corrections and direct gene insertions.

      The impact of the CRISPR/Cas9 system on drug discovery spans from creation of cellular models, to functional genomics screens that support target identification.  These screens may provide a wealth of data on the normal function of the target genes and may also yield better validated targets for directed small molecule or biologic therapeutics.  Ultimately, the hits from these screens can be followed up by using CRISPR technology to generate animal knockout models that could support translating the screen to a pre-clinical trial. This trial, in turn, could provide better correlation to the clinical setting and thereby reduce candidate drug attrition. Here we discuss the application of CRISPR/Cas9 screening in select cellular models ranging from a reporter assay based system to phenotypic assays. 

      Show Resources
      Loading Comments...